Catalyst Pharmaceutical Partners Signals Confident Growth Path

Catalyst Pharmaceutical Partners ((CPRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Catalyst Pharmaceutical Partners’ latest earnings call struck an upbeat tone, underscoring strong double-digit revenue growth, record product performance, and a fortified cash position. Management balanced this optimism with candor on headwinds such as FYCOMPA erosion, IRA-related pricing pressure, and patent risk, but stressed these are manageable against a backdrop of outperformance and solid 2026 guidance.

Record Revenues Beat Expectations

Total revenues for 2025 reached $589.0 million, up 19.8% year over year and above the prior guidance range of $565 million to $585 million. Net product revenue was $588.8 million, rising 20.3% versus 2024 and signaling that core commercial franchises are scaling faster than management had initially projected.

FIRDAPSE Remains the Growth Engine

FIRDAPSE delivered net product revenue of $358.4 million in 2025, a 17% increase year over year, with Q4 sales of $97.6 million up 18.3% versus Q4 2024 and 5.9% sequentially. For 2026, management guided FIRDAPSE revenues to a robust $435 million to $450 million, implying growth of roughly 21.4% to 25.6% despite mounting reimbursement headwinds.

AGAMREE’s Launch Momentum Accelerates

AGAMREE posted $117.1 million in 2025 net product revenue, soaring 154.3% from the prior year, with Q4 sales of $35.3 million up 67.5% versus Q4 2024. The drug is now adopted at 100% of top DMD centers of excellence, covering about 80% of DMD patients, and 270 unique prescribers have submitted enrollment forms.

FYCOMPA Still Contributes Despite Generics

FYCOMPA generated $113.3 million in 2025 revenue even after losing exclusivity in May and facing multiple generic entrants. Management now expects FYCOMPA to contribute a more modest $40 million to $45 million in 2026 and has halted active promotion, but still sees it as a meaningful cash generator in the portfolio.

Profitability and Cash Reserves Strengthen

Net income before taxes climbed 31.1% to $283.5 million in 2025, while GAAP net income rose 30.8% to $214.3 million, or $1.68 per diluted share. Non-GAAP net income reached $346.2 million, or $2.72 per diluted share, and year-end cash and equivalents swelled to $709.2 million from $517.6 million, fueled by $208.7 million of operating cash flow.

Improved Commercial Execution in Rare Disease

For FIRDAPSE, data leads of identified LEMS patients in active diagnostic stages rose 40% in Q4 2025, with over 600 patients now in the identified pool. VGCC testing increased about 21% year over year and more than one-third in H2 versus H1 2025, while a new pharmacy intervention program reduced early discontinuations by roughly 12%.

AGAMREE Demand Appears Durable

AGAMREE is seeing reimbursement success rates above 85%, with management indicating they trend closer to 90%, supporting consistent access. Discontinuations and cancellations fell meaningfully in the second half of 2025, with about 45% of patients switching from prednisone and 42% from EMFLAZA, and a lower median enrollee age suggesting earlier-line use.

Business Development Engine Scales Up

The company’s business development team evaluated more than 100 opportunities in 2025, with roughly 90% coming inbound, underscoring Catalyst’s growing industry visibility. The search mandate has expanded to later-stage assets with clear regulatory paths and peak sales potential up to $500 million to complement organic growth from existing franchises.

Advancing Clinical and Life-Cycle Programs

AGAMREE’s life-cycle strategy includes the ongoing five-year SUMMIT study targeting about 250 patients to generate long-term safety and benefit data. A Phase I study is also assessing dose equivalence and immunosuppressive biomarkers, with analysis expected in the first half of 2026 to support differentiation and potential label or indication expansion.

FYCOMPA Erosion and Patent Overhang

Generic competition for FYCOMPA, which began in May 2025, is driving a sharp step down in expected 2026 revenue from $113.3 million to $40 million to $45 million. While settlements have been obtained with two of three first filers, a key patent case against Hetero USA is heading to trial in March 2026, leaving some uncertainty around longer-term IP protection.

Rising Costs, Royalties, and IRA Headwinds

Cost of sales rose to about $87.3 million in 2025 from $68.8 million, mainly due to higher royalties, while SG&A increased to $193.8 million from $177.7 million on compensation and added headcount. AGAMREE triggered a $12.5 million milestone at $100 million in sales, and layered royalty structures plus IRA-driven gross-to-net pressure, especially in Medicare Part D, are expected to weigh on margins.

Label and Retention Frictions Being Addressed

AGAMREE’s commercial pitch is currently constrained because encouraging long-term data from external sources and SUMMIT are not yet in the official label. Management also acknowledged early FIRDAPSE discontinuations were higher than expected in the first four months, but noted the recently launched pharmacy program has cut these early drop-offs by roughly 12%.

Steady Investment in R&D and SG&A

R&D spending was essentially flat at $12.7 million in 2025 versus $12.6 million in 2024, but is guided to increase to $17.5 million to $22.5 million in 2026, excluding any acquisitions. SG&A is expected to rise modestly from the current $193.8 million as Catalyst invests to support FIRDAPSE’s expansion in cancer-associated LEMS, which may slightly temper near-term margin expansion.

Forward-Looking Guidance and Outlook

For 2026, Catalyst guided total revenues of $615 million to $645 million, with FIRDAPSE expected to deliver $435 million to $450 million, AGAMREE $140 million to $150 million, and FYCOMPA $40 million to $45 million. Management also projected R&D spending of $17.5 million to $22.5 million, a slight SG&A increase, and FYCOMPA royalties beginning mid-2026, while acknowledging rising IRA headwinds in Medicare Part D.

Catalyst’s earnings call painted the picture of a company executing well on its core rare-disease franchises while preparing for external pressures and portfolio transitions. With strong revenue growth, robust cash generation, and disciplined investment, management framed 2026 as a year of continued expansion, even as generic erosion, regulatory shifts, and IP challenges remain key risks for investors to watch.